AbbVie (ABBV) Q4 2023: Ex-Humira Growth Platform Surges 15%, Powering Post-LOE Recovery

2024-02-02 | By EarningsIQ Research

AbbVie’s diversified growth platform delivered a 15 percent sales surge excluding Humira, decisively offsetting biosimilar headwinds and setting up a return to growth in 2024. Robust execution across immunology, neuroscience, and aesthetics, alongside pipeline investments and M&A, underpins management’s conviction in a high single-digit CAGR through the decade. Investors face a transition year for Humira, but the portfolio’s momentum and capital allocation discipline position AbbVie for renewed expansion.

Summary

• Immunology and Neuroscience Outperform: Ex-Humira brands and migraine franchise drive broad-based growth.
• Pipeline and M&A Execution Accelerate: R&D expansion and Immunogen, Cerevel deals strengthen long-term outlook.
• Near-Term Focus Shifts to Margin Expansion: Management signals operating leverage and dividend support as topline recovers.

Business Overview

AbbVie is a global biopharmaceutical company that generates revenue from branded therapeutics across immunology, oncology, neuroscience, aesthetics, and eye care. The immunology segment (Skyrizi, Rinvoq, Humira) remains the largest, but neuroscience (Vraylar, Botox Therapeutic, CGRP migraine franchise), oncology (Imbruvica, Venclexta), and aesthetics (Botox Cosmetic, Juvederm) are increasingly material. The business model blends established blockbusters, new launches, and pipeline innovation, with a focus on high-margin specialty drugs and global market access.

Performance Analysis

AbbVie’s Q4 marked a pivotal inflection as the company absorbed the full impact of U.S. Humira biosimilar erosion yet delivered strong performance from its ex-Humira growth platform, which grew 15 percent operationally. Immunology’s Skyrizi and Rinvoq posted impressive operational sales growth of 52 percent and 63 percent, respectively, with combined annual revenue now exceeding $11.7 billion and a raised 2027 outlook. Neuroscience was another highlight, with Vraylar up nearly 40 percent and the CGRP migraine portfolio surpassing expectations, prompting a $1 billion increase in peak sales guidance for this category.

Aesthetics rebounded in the U.S. as Botox Cosmetic and Juvederm posted mid-to-high single-digit growth, although China remained a drag due to ongoing economic headwinds. Oncology results were mixed, with Imbruvica declining 19 percent but Venclexta and new launches offsetting some of the pressure. Operating margins remained strong (43.8 percent adjusted), reflecting cost discipline and robust gross margins even as R&D investment was stepped up by $600 million.

• Immunology Share Gains: Skyrizi and Rinvoq are capturing outsized “in-play” patient share in IBD and dermatology, supporting future prescription growth.
• Neuroscience Expansion: Migraine and Parkinson’s launches (ABBV951) are broadening the portfolio’s reach and deepening market penetration.
• Aesthetics Resilience: U.S. demand offset China softness, with innovation in fillers and toxins sustaining leadership.

Cash flow was robust and the dividend was increased for the eleventh consecutive year, underscoring AbbVie’s commitment to shareholder returns even during a major LOE transition.

Executive Commentary

Strategic Positioning

1. Immunology Leadership and Share Capture

AbbVie’s immunology franchise, led by Skyrizi and Rinvoq, is outpacing competitors by capturing disproportionate “in-play” patient share in IBD, psoriasis, and atopic dermatitis. Management raised 2027 combined sales guidance for these assets to over $27 billion, reflecting both market expansion and new indications. The business is leveraging a dual-mechanism approach in IBD (Skyrizi for frontline, Rinvoq for later lines), minimizing cannibalization and maximizing total share.

2. Neuroscience and Migraine Growth Engines

Neuroscience revenue exceeded $7.7 billion for the year, up $1.2 billion, as Vraylar and the oral CGRP migraine portfolio (Ubrelvy, Qulipta) gained momentum. The launch of ABBV951 for advanced Parkinson’s disease and expansion into international markets position AbbVie to capture underpenetrated segments and establish new high-efficacy categories. Management expects continued robust growth as new indications and geographies come online.

3. Oncology Pipeline and ADC Expansion

The pending Immunogen acquisition brings first-in-class ADC (antibody-drug conjugate) assets into AbbVie’s solid tumor pipeline, with Elahere’s U.S. launch in ovarian cancer already showing strong uptake. Additional pipeline assets (e.g., Teliso-V, ABBV383 for multiple myeloma) are advancing, with management emphasizing accelerated approvals and combination strategies to broaden addressable markets.

4. Aesthetics Market Recovery and Innovation

U.S. aesthetics rebounded as patient demand and digital engagement metrics improved. Botox Cosmetic remains the market leader, and new launches (Volux, Skindiv in fillers) are driving incremental growth. While China remains a near-term headwind, AbbVie’s innovation pipeline in toxins and regenerative fillers is aimed at sustaining high-single-digit annual growth and exceeding $9 billion in sales by decade’s end.

5. Capital Allocation and Margin Discipline

AbbVie’s capital allocation remains balanced, with $12.8 billion in cash, $18 billion in expected 2024 free cash flow, and a continued focus on dividend growth and debt repayment. Operating margin is forecast to expand in 2025 and beyond, even as R&D investment increases to support late-stage pipeline assets and M&A integration.

Key Considerations

AbbVie’s quarter demonstrates the execution necessary to manage a major LOE event while investing for future growth. The company’s ability to drive double-digit growth in its base business, raise long-term guidance for key franchises, and maintain capital return priorities reflects a well-diversified platform.

Key Considerations:

• Immunology Durability: Significant headroom remains in biologic penetration and line expansion, with new indications for Rinvoq expected to drive outsized growth beyond 2027.
• Pipeline Catalysts: Multiple phase 3 readouts and regulatory submissions in immunology, oncology, and neuroscience could unlock new multi-billion-dollar opportunities.
• M&A Integration Execution: Successful closing and integration of Immunogen and Cerevel are critical for expanding oncology and neuroscience pipelines.
• Aesthetics Market Dynamics: U.S. recovery is robust, but China’s economic headwinds and filler market lag require close monitoring.
• Margin and Tax Rate Trajectory: Operating margin expansion is expected, but global tax policy changes (GILTI, OECD) will modestly increase the effective tax rate over the next three years.

Risks

The principal risks center on continued Humira erosion, biosimilar pricing pressure, and the pace of market share capture for new immunology and neuroscience launches. China’s economic slowdown and potential IRA (Inflation Reduction Act) impacts on Medicare pricing represent additional headwinds. Pipeline execution, especially for new ADC assets and neuroscience launches, carries development and regulatory risk. Global tax changes and integration of major acquisitions add further complexity.

Forward Outlook

For Q1 2024, AbbVie guided to:

• Net revenues of approximately $11.9 billion, with immunology at $5.1 billion and neuroscience at $1.9 billion.
• Adjusted earnings per share between $2.30 and $2.34, excluding acquired IPR&D expense.

For full-year 2024, management reaffirmed:

• Adjusted EPS of $11.05 to $11.25, including acquisition-related dilution.
• Total net revenues of $54.2 billion, reflecting a return to modest operational growth.

Management highlighted operating margin expansion, robust free cash flow, and dividend support as priorities, with growth acceleration expected in 2025 and a high single-digit CAGR through the decade.

• Skyrizi and Rinvoq combined sales are forecast to exceed $27 billion by 2027.
• Integration of Immunogen and Cerevel expected mid-year, with incremental revenue contribution in H2.

Takeaways

AbbVie’s diversified portfolio is absorbing the Humira LOE shock faster than expected, with ex-Humira assets powering a return to growth and margin expansion in 2024.

• Immunology and Neuroscience Drive Recovery: Skyrizi, Rinvoq, and Vraylar are capturing share and expanding into new indications, offsetting legacy erosion.
• Pipeline and M&A Bolster Long-Term Growth: Strategic investments in ADCs and neuropsychiatry assets set the stage for a multi-year growth cycle.
• Watch for Execution on Integration and Margin Expansion: The next year will test AbbVie’s ability to deliver on guidance as it integrates major acquisitions and ramps late-stage launches.

Conclusion

AbbVie’s Q4 results reinforce the company’s ability to manage through patent cliffs and sustain growth through innovation and disciplined execution. The combination of strong commercial momentum, pipeline progress, and capital allocation discipline positions AbbVie as a differentiated large-cap biopharma entering a new phase of expansion.

Industry Read-Through

AbbVie’s rapid rebound from Humira LOE highlights the value of a diversified specialty portfolio and disciplined pipeline execution for large-cap pharma peers. The company’s success in immunology share capture, neuroscience expansion, and ADC pipeline build-out sets a benchmark for managing loss of exclusivity and biosimilar headwinds. The performance of U.S. aesthetics amid China softness signals that regional demand recovery can offset global volatility for consumer-facing therapeutics. Investors in the sector should monitor M&A integration, margin discipline, and the evolving impact of U.S. drug pricing reforms, as these will shape the competitive landscape and valuation frameworks across biopharma.

ABBV Healthcare Pharmaceuticals Immunology Neuroscience Aesthetics Biosimilars Pipeline